TY - JOUR
T1 - DT5aP-Hib-IPV and MCC vaccines
T2 - Preterm infants' response to accelerated immunisation
AU - Slack, M. H.
AU - Cade, S.
AU - Schapira, D.
AU - Thwaites, R. J.
AU - Crowley-Luke, A.
AU - Southern, Joanna
AU - Borrow, Raymond
AU - Miller, Elizbeth
PY - 2005/4
Y1 - 2005/4
N2 - Aims: To describe the immune response of preterm infants to combined diphtheria/tetanus/5 component acellular pertussis-Haemophilus influenzae type b inactivated polio vaccine (DT5aP-Hib-IPV) and meningococcal serogroup C conjugate vaccine (MCC) under accelerated schedule. To compare results with term infants immunised with DT5aP-Hib-IPV and with historical data from preterm infants immunised with a DT3 component aP-Hib vaccine. Methods: Prospective observational study in preterm infants born at <32 weeks gestation with comparison to contemporary cohort of term infants. DT5aP-Hib-IPV and MCC vaccines were given at 2, 3, and 4 months. Results: Fifty preterm infants (mean gestational age 28.5 weeks) completed the study. After three doses of vaccines Hib polysaccharide IgG geometric mean concentration (GMC) was 1.21 μg/ml with 80% ≥0.15 μg/ml; MCC serum bactericidal assay geometric mean titre (GMT) was 1245 with 100% ≥8. All infants achieved protective titres to diphtheria, tetanus, and the three poliovirus types with ≥80% achieving protective rises in IgG against the five pertussis antigens. Conclusion: Preterm infants immunised with DT5aP-Hib-IPV and MCC vaccines show IgG responses to Hib and MCC greater than seen historically in both term and preterm infants with a DT3aP-Hib vaccine, and for pertussis antigens and poliovirus type 1 responses similar to that seen in term infants immunised with DT5aP-Hib-IPV. Responses to poliovirus types 2 and 3 are reduced, but all infants achieved protective titres.
AB - Aims: To describe the immune response of preterm infants to combined diphtheria/tetanus/5 component acellular pertussis-Haemophilus influenzae type b inactivated polio vaccine (DT5aP-Hib-IPV) and meningococcal serogroup C conjugate vaccine (MCC) under accelerated schedule. To compare results with term infants immunised with DT5aP-Hib-IPV and with historical data from preterm infants immunised with a DT3 component aP-Hib vaccine. Methods: Prospective observational study in preterm infants born at <32 weeks gestation with comparison to contemporary cohort of term infants. DT5aP-Hib-IPV and MCC vaccines were given at 2, 3, and 4 months. Results: Fifty preterm infants (mean gestational age 28.5 weeks) completed the study. After three doses of vaccines Hib polysaccharide IgG geometric mean concentration (GMC) was 1.21 μg/ml with 80% ≥0.15 μg/ml; MCC serum bactericidal assay geometric mean titre (GMT) was 1245 with 100% ≥8. All infants achieved protective titres to diphtheria, tetanus, and the three poliovirus types with ≥80% achieving protective rises in IgG against the five pertussis antigens. Conclusion: Preterm infants immunised with DT5aP-Hib-IPV and MCC vaccines show IgG responses to Hib and MCC greater than seen historically in both term and preterm infants with a DT3aP-Hib vaccine, and for pertussis antigens and poliovirus type 1 responses similar to that seen in term infants immunised with DT5aP-Hib-IPV. Responses to poliovirus types 2 and 3 are reduced, but all infants achieved protective titres.
UR - http://www.scopus.com/inward/record.url?scp=16844370387&partnerID=8YFLogxK
U2 - 10.1136/adc.2004.052720
DO - 10.1136/adc.2004.052720
M3 - Article
C2 - 15781918
AN - SCOPUS:16844370387
SN - 0003-9888
VL - 90
SP - 338
EP - 341
JO - Archives of Disease in Childhood
JF - Archives of Disease in Childhood
IS - 4
ER -
